190 related articles for article (PubMed ID: 6197309)
1. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
[TBL] [Abstract][Full Text] [Related]
2. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
Waldmeier PC; Baumann PA
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
[TBL] [Abstract][Full Text] [Related]
3. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
Kato T; Dong B; Ishii K; Kinemuchi H
J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
6. On the reversibility of reversible MAO inhibitors.
Waldmeier PC
Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
[TBL] [Abstract][Full Text] [Related]
7. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Waldmeier PC; Delini-Stula A; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of rat brainstem monoamine oxidase activity by CGP 6085 A.
Hurst JH; Kulakowski EC
Life Sci; 1986 Oct; 39(16):1471-7. PubMed ID: 2430159
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens.
Pepper JP; Baumann MH; Ayestas M; Rothman RB
Brain Res Mol Brain Res; 2001 Mar; 87(2):184-9. PubMed ID: 11245920
[TBL] [Abstract][Full Text] [Related]
10. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
Celada P; Artigas F
J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
[TBL] [Abstract][Full Text] [Related]
11. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
[TBL] [Abstract][Full Text] [Related]
12. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
Sivam SP
Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
[TBL] [Abstract][Full Text] [Related]
13. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
14. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
15. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
Kumagae Y; Matsui Y; Iwata N
Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
[TBL] [Abstract][Full Text] [Related]
16. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.
Hazelhoff B; De Vries JB; Dijkstra D; de Jong W; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):50-8. PubMed ID: 2413370
[TBL] [Abstract][Full Text] [Related]
17. Chronic effect of the irreversible and reversible selective MAO-A inhibitors on rat pineal melatonin biosynthesis.
Oxenkrug GF; Requintina PJ; McIntyre IM; White K
J Neural Transm Suppl; 1994; 41():381-4. PubMed ID: 7523585
[TBL] [Abstract][Full Text] [Related]
18. Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release.
Halladay AK; Kirschner E; Hesse K; Fisher H; Wagner GC
Pharmacol Toxicol; 2001 Nov; 89(5):237-48. PubMed ID: 11881977
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
20. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
